

Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets

Nikoleta Bizymi^{1,2}, Sunčica Bjelica³, Astrid Olsnes Kittang^{4,5}, Slavko Mojsilovic⁶, Maria Velegraki^{1,7}, Charalampos Pontikoglou¹, Mikael Roussel^{8,9,10}, Elisabeth Ersvær¹¹, Juan Francisco Santibañez^{3,12}, Marie Lipoldová¹³, Helen A. Papadaki¹

Correspondence: Helen A. Papadaki (e-mail: e.papadaki@uoc.gr).

Abstract

Myeloid-derived suppressor cells (MDSC) are a heterogeneous group of immature myeloid cells that exist at very low numbers in healthy subjects but can expand significantly in malignant, infectious, and chronic inflammatory diseases. These cells are characterized as early-MDSCs, monocytic-MDSCs, and polymorphonuclear-MDSCs and can be studied on the basis of their immunophenotypic characteristics and their functional properties to suppress T-cell activation and proliferation. MDSCs have emerged as important contributors to tumor expansion and chronic inflammation progression by inducing immunosuppressive mechanisms, angiogenesis and drug resistance. Most experimental and clinical studies concerning MDSCs have been mainly focused on solid tumors. In recent years, however, the implication of MDSCs in the immune dysregulation associated with hematologic malignancies, immune-mediated cytopenias and allogeneic hemopoietic stem cell transplantation has been documented and the potential role of these cells as biomarkers and therapeutic targets has started to attract a particular interest in hematology. The elucidation of the molecular and signaling pathways associated with the generation, expansion and function of MDSCs in malignant and immune-mediated hematologic diseases and the clarification of mechanisms related to the circulation and the crosstalk of MDSCs with malignant cells and other components of the immune system are anticipated to lead to novel therapeutic strategies. This review summarizes all available evidence on the implication of MDSCs in hematologic diseases highlighting the challenges and perspectives arising from this novel field of research.

Introduction

References to cells of myeloid origin that promote tumor progression through immune evasion mechanisms while also induce inflammatory and hemopoietic responses, go back to the

1970s.¹ These myeloid cells display immunosuppressive properties and expand particularly in neoplastic, infectious, and inflammatory diseases; they were initially characterized as *natural suppressor* or *veto* or *null cells* because of the absence of surface

Funding: This work was supported by COST (European Cooperation in Science and Technology) and the COST Action BM1404 Mye-EUNITER (<http://www.mye-euniter.eu>). COST is part of the EU Framework Programme Horizon 2020. This work was also supported by the Alexander S. Onassis, Public Benefit Foundation in Greece Scholarship to NB.

Authors' contribution: HAP conceptualized the review. All authors contributed to the writing and editing of the review. All authors approved the final version.

Disclosure: The authors have indicated they have no potential conflicts of interest to disclose.

¹Hemopoiesis Research Laboratory, School of Medicine, University of Crete and Department of Hematology, University Hospital of Heraklion, Heraklion, Greece

²Graduate Program Molecular Basis of Human Disease, School of Medicine, University of Crete, Heraklion, Greece

³Department of Molecular Oncology, Institute for Medical Research, University of Belgrade, Belgrade, Republic of Serbia

⁴Department of Clinical Science, University of Bergen, Bergen, Norway

⁵Division of Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway

⁶Laboratory of Experimental Hematology and Stem Cells, Institute for Medical Research, University of Belgrade, Belgrade, Serbia

⁷Department of Immunology and Microbiology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA

⁸CHU de Rennes, Pole de Biologie, Rennes, France

⁹INSERM, UMR U1236, Université Rennes 1, EFS Bretagne, Equipe Labellisée Ligue Contre le Cancer, Rennes, France

¹⁰Laboratoire d'Hématologie, CHU Pontchaillou, Rennes Cedex, France

¹¹Department of Biomedical Laboratory Scientist Education, Western Norway University of Applied Sciences, Bergen, Norway

¹²Centro Integrativo de Biología y Química Aplicada (CIBQA), Universidad Bernardo O'Higgins, Santiago, Chile

¹³Laboratory of Molecular and Cellular Immunology, Institute of Molecular Genetics AS CR, Prague, Czech Republic

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

HemaSphere (2019) 3:1(e168)

Received: 31 August 2018 / Accepted: 26 November 2018

Citation: Bizymi N, Bjelica S, Kittang AO, Mojsilovic S, Velegraki M, Pontikoglou C, Roussel M, Ersvær E, Santibañez JF, Lipoldová M, Papadaki HA. Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets. *HemaSphere*, 2019;3:1. <http://dx.doi.org/10.1097/HS9.000000000000168>

markers of T-cells, B-cells, natural killer (NK) cells or macrophages and later as *immature myeloid cells* or *myeloid suppressor cells* to denote their main biologic properties.¹ In 2007, the term myeloid derived suppressor cells (MDSCs) was introduced as the best to reflect the origin and functional trait of these cells despite the heterogeneity in their phenotypic, genomic and biochemical characteristics.² In recent years, MDSCs have been recognized as important immune regulators, potential biomarkers and even therapeutic targets in cancer and other diseases associated with chronic inflammation including infectious diseases, autoimmune diseases and trauma, among others.^{3,4}

In humans, MDSCs are identified as CD11b⁺CD33⁺HLA-DR^{-low} cells.⁵ They can be further divided into 2 distinct populations with the main difference being the expression of CD14 (monocytic—MDSCs, M-MDSCs) or CD15 (polymorphonuclear—MDSCs, PMN-MDSCs) surface molecules. M-MDSCs are morphologically identical to conventional monocytes from which they can be distinguished on the basis of HLA-DR expression. PMN-MDSCs can be distinguished from conventional PMN based on their low-density properties following centrifugation over density gradient as well as on the expression of the lectin type oxidized LDL receptor 1 (LOX-1).^{3,6} A third, minor population of MDSCs has been recognized, the early-stage MDSCs (e-MDSCs), which express neither CD15 nor CD14; these cells are characterized as Lin⁻ (CD3, CD14, CD15, CD19, CD56)HLA-DR⁻CD33⁺ and comprise immature progenitor and precursor cells with myeloid colony-forming activity.⁵ In mice, MDSCs are characterized by the expression of Gr1 and CD11b and can also be divided into PMN-MDSCs (CD11b⁺Ly6G⁺Ly6C^{low} cells), M-MDSCs (CD11b⁺Ly6G⁺Ly6C^{high}), and non-PMN-MDSCs/non-M-MDSCs (CD11b⁺Ly6G^{med}Ly6C^{med} cells).^{5,7} Notably, the term granulocytic-MDSCs (G-MDSCs) has previously been used for the definition of PMN-MDSCs in both human and mice.

The precise mechanisms underlying the generation of MDSCs remain largely unknown. MDSCs are likely to arise under inflammatory conditions when there is an increased demand for myeloid cells (emergency myelopoiesis); they then expand as immature cells in the bone marrow (BM) or even extramedullary (mainly in the spleen) and migrate into the peripheral blood (PB) where their terminal differentiation is blocked finally transforming into functionally active MDSCs. According to this model, 2 signals are required for MDSCs' generation; the expansion/mobilization signal mediated mainly through growth factors such as granulocyte and granulocyte/monocyte colony stimulating factors (G-CSF and GM-CSF, respectively) and proinflammatory mediators such as interleukin-6 (IL-6) and prostaglandin E2 (PGE2) resulting in upregulation of the signal transducer and activator of transcription (STAT)-3 in myeloid progenitor cells; and the activation signal mediated through proinflammatory stimuli such as lipopolysaccharides (LPS), PGE2, IL-1 and S100A8/A9 resulting in NF- κ B upregulation and induction of the suppressive MDSC phenotype. Recent evidence suggests that M-MDSCs may also arise by reprogramming of monocytes through pathogen- or danger-associated molecular patterns (PAMPs or DAMPs, respectively) and Toll-like receptor (TLR) activation as well as through certain cytokines and mediators such as IL-10, Wnt5a, and PGE2.⁸ Another hypothesis, although still controversial, indicates that PMN-MDSCs may represent an activation stage of PMNs derived from immature or mature granulocytes⁸ (Fig. 1).

The fundamental functional characteristic of MDSCs is the capacity to suppress immune cells, predominantly T-cells and to a lesser degree B-cells and NK-cells.^{1,3,9} Main transcription factors involved in the suppressive function of MDSCs include STAT3, hypoxia inducible factor 1a (HIF-1a) and CCAAT/enhancer binding protein b (C/EBPb).^{1,3,9} Effector molecules produced by MDSCs include arginase-1, which induces L-arginine deprivation and causes nitrosylation and down-regulation of the CD3z part of the T-cell receptor complex; cyclooxygenase (COX)-2 and indoleamine 2,3-dioxygenase (IDO); inducible nitric oxide synthase (iNOS), which leads to the production of NO, induction of T-cell apoptosis and suppression of T-cell proliferation; NADPH oxidase 2 (NOX2), which inhibits the proliferation of T-cells through production of reactive oxygen species (ROS) and nitration of CD3z and major histocompatibility complex (MHC)-I; heme oxygenase 1 (HO-1) which also inhibits T-cell proliferation through carbon monoxide (CO) production; mediators reducing cysteine provision to T-cells by antigen presenting cells; membrane-bound transforming growth factor β 1 (TGF β 1), which promotes the anergy of NK-cells and the development of regulatory T cells (Treg); IL-10, which leads to Th2 deviation and type 2 polarization of macrophages; and ADAM metalloproteinase domain 17 (ADAM17) which cleaves L-selectin (CD62L) from T-cells leading to their homing in lymph nodes and sites of inflammation.^{1,3,9} In addition to their immune-suppressive properties, MDSCs promote tumor progression and metastasis by affecting the remodeling of the tumor microenvironment and tumor angiogenesis via production of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and matrix metalloproteinase-9 (MMP9).^{1,3,9}

The immune system displays a prominent role in the pathogenesis, pathophysiology and response to treatment of patients with hematologic malignancies, BM failure syndromes and autoimmune disorders^{10,11}; therefore, immune modulating agents (i.e., lenalidomide, monoclonal antibodies, hypomethylating drugs, signal transduction inhibitors among others) have significantly improved the outcome of these patients.^{10,11} As expected, the possible implication of MDSCs in the immune dysregulation associated with these disease entities and their potential role as biomarkers and therapeutic targets has started to attract a particular interest in hematology.^{10,11} This is further triggered by the fact that MDSCs in addition to their immunosuppressive properties on T-cells can also interact with the mesenchymal stromal cells (MSCs) in the BM through shared molecules and mechanisms and this interplay may alter the immunoregulatory properties of the BM microenvironment and consequently, the disease pathophysiology and response to treatment.¹² This review summarizes all available evidence on the implication of MDSCs in hematologic malignancies and immune-mediated BM failure syndromes and cytopenias highlighting the challenges and perspectives arising from this novel field of research.

Myeloproliferative neoplasms and acute leukemia

Myeloproliferative neoplasms (MPNs) are a group of hemopoietic stem cell disorders characterized by clonal proliferation of myeloid-lineage cells and chronic inflammation.¹³ Classic MPNs include chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis




Figure 1. Proposed signals for MDSC generation. In humans, MDSCs are identified as $CD11b^+CD33^+HLA-DR^{-/low}$ cells and are classified by the expression of CD14 as monocytic-MDSCs (M-MDSCs) or CD15 as polymorphonuclear-MDSCs (PMN-MDSCs). A minor population of MDSCs, the early stage MDSCs (e-MDSCs), expresses neither CD15 nor CD14. The fundamental functional characteristic of MDSCs is the capacity to suppress immune cells, predominantly T-cells and to a lesser degree B-cells and NK-cells. MDSCs arise under inflammatory conditions due to an increased demand for myeloid cells (emergency myelopoiesis); they expand from the hematopoietic stem cell (HSC) as immature cells in the bone marrow (BM) or extramedullary, and migrate into the peripheral blood (PB) where their terminal differentiation is blocked transforming into functionally active MDSCs. Two types of signals are required for MDSCs' generation: the expansion/mobilization signal through growth factors such as granulocyte and granulocyte/monocyte colony stimulating factors (G-CSF and GM-CSF, respectively) and proinflammatory mediators such as interleukin-6 (IL-6) and prostaglandin E2 (PGE2) resulting in upregulation of STAT3 in myeloid progenitor cells; and the activation signal mediated through proinflammatory stimuli such as lipopolysaccharides (LPS), PGE2, IL-1, and S100A8/A9 resulting in NF- κ B upregulation and induction of the suppressive MDSC phenotype. M-MDSCs may also arise by reprogramming of monocytes through pathogen- or danger-associated molecular patterns (PAMPs or DAMPs, respectively) and Toll-like receptor (TLR) activation as well as through certain cytokines and mediators such as IL-10, Wnt5a, and PGE2. PMN-MDSCs may also represent an activation stage of PMNs derived from immature or mature granulocytes.

(PMF). Studies on MDSCs in CML have demonstrated increased frequency of PMN-MDSC subsets in Sokal high-risk patients, expressing high levels of programmed death receptor ligand-1/programmed death receptor-1 (PD-L1/PD-1) and arginase-1.^{14,15} Increased PMN-MDSC and M-MDSC subsets in CML patients at diagnosis have been shown to return to normal levels after treatment with the tyrosine kinase inhibitor (TKI) imatinib and M-MDSCs frequency has been proposed as a prognostic factor in CML patients receiving the TKI dasatinib.¹⁶ Overall, CML patients appropriately responding to TKI therapies (imatinib, nilotinib, dasatinib), parallel to the reduction of *abl-bcr* transcripts display a decrease in M-MDSC frequency and immunosuppressive activity and restoration of T-cell and NK-cell immune functions.¹⁷ Recent evidence also suggests that MDSCs may have a critical role in CML malignant cell immune escape. In particular, it has been shown that the malignant cell

expansion in CML is maintained by a small subset of $CD34^+/CD38^-$ leukemic stem cells that may escape immune cell surveillance within immunosuppressive BM niches consisting of populations of MSCs and PMN-MDSCs with T-cell suppressive capacity.¹⁸ It is therefore reasonable to hypothesize that targeting of MDSCs in CML may restore the T-cell mediated leukemia surveillance and improve further patients' long-term outcome.

As regards to the Philadelphia negative MPNs, namely PV, ET, and PMF, a number of studies have documented abnormal reserves and function of immune cells including increase of monocyte/macrophages, altered regulatory T-cell frequency, NK-cell dysfunction, and expansion of MDSCs.¹⁹ Recent evidence also suggests that although MDSCs are significantly elevated in MPNs, no differences can be identified in their frequency among different MPN categories and no correlations with JAK2 allele

burden can be made.²⁰ MPN-derived MDSCs have also been shown to display significantly elevated arginase-1 mRNA and T-cell suppressive activity.²⁰

There are only a few studies on MDSCs in acute leukemias clearly showing the negative impact of their presence on the disease prognostic characteristics. A recent study has shown variable but significantly higher number of MDSCs, defined as CD14⁻HLA-DR⁻CD33⁺CD11b⁺ cells, in PB of patients with acute myeloid leukemia (AML) compared to patients with acute lymphoblastic leukemia (ALL) and significant correlation of AML-MDSCs with conventional prognostic factors at diagnosis, namely WBC count, CD34 frequency and nucleophosmin (NPM1) and *fms*-like tyrosine kinase 3 (FLT3) gene mutations. It has also been shown that CD33⁺CD11b⁺HLA-DR^{-low} MDSCs accumulate in the BM of AML patients and their presence may have an impact on disease prognosis and patients' clinical course.²¹ Furthermore, MDSCs levels in newly diagnosed AML patients have been reported to correlate with AML subtype, presence of chromosomal abnormalities and gene alterations, extramedullary involvement, and plasma D-dimer levels. After the induction therapy, MDSCs significantly decrease in patients with complete remission but not in patients with partial or no response while on follow-up and MDSCs' frequency correlate with minimal residual disease (MRD) levels and Wilms 1 (WT-1) gene detection.²¹ Another study has shown expansion of MDSCs from PB mononuclear cells (PBMCs) following contact with AML cell lines or primary AML cells via tumor-derived extracellular vesicles; it has been postulated that the mucin 1 (MUC1) oncoprotein induces increased expression of *c-myc* in extracellular vesicles that are then taken-up by the myeloid progenitor cells resulting in downstream effects on cell cycle proteins and selective proliferation of MDSCs.²² As regards to ALL, it has been shown that pediatric patients with B-cell ALL display increased number of PMN-MDSCs in PB and BM compared to age-matched healthy individuals and PMN-MDSC frequency correlate with prognostic markers such as MRD and CD20⁺ blast cell counts as well as with response to therapy.^{23,24} PMN-MDSCs from patients in remission have been reported to lose their suppressive function corroborating the effect of these cells in mediating immune evasion mechanisms.^{23,24} All these observations and available evidence implicating MDSCs in both AML and ALL progression and outcome highlight the emerging role of these cells as independent biomarkers and promising targets for the development of novel therapeutic strategies.

Myelodysplastic syndromes

Myelodysplastic syndromes (MDS) are clonal hemopoietic stem cell disorders characterized by PB cytopenias, dysplastic changes in one or more BM cell lineages and increased risk of AML.²⁵ Allogeneic hemopoietic stem cell transplantation (Allo-HSCT) with donor T-cell reactivity against the malignant cells is the only curative therapy for MDS. BM microenvironment in low-risk MDS is characterized by persistent inflammation and expansion of autoimmunity-associated T-helper 17 (Th17) cells whereas expansion of MDSCs and Tregs and reduced number of Th17 characterize high-risk MDS.^{26,27} Lin⁻(CD3/CD14/CD16/CD19/CD20/CD56)HLA-DR⁻CD33⁺ MDSCs in high-risk MDS are capable to induce apoptosis of erythroid precursor cells and their expansion is driven, at least in part, by the interaction of S100A9 protein with the CD33

cell surface antigen.²⁸ Immune phenotyping with mass cytometry and unsupervised viSNE analysis of 35-markers per cell of thawed MDS and AML BM samples has revealed that one of the strongest marker signals was the expression of S100A9. This protein is seen in multiple cell types including MDSCs and its expression was more common in MDS without excess of blasts. S100A9 mainly characterizes M-MDSCs and together with its binding partner, S100A8, is included in the DAMP molecules displaying intra- and extracellular functions and inflammatory, antiinflammatory and immune regulatory properties.^{29,30} Varying S100A9 expression resulted in different MDSC functions, with more proinflammatory effect in low risk and immunosuppressive effect in high-risk MDS. S100A9 and CD33 ligand/receptor pair interactions recruit components to the immunoreceptor tyrosine-based inhibition motif (ITIM) finally resulting in secretion of suppressive IL-10 and TGFβ1.²⁸ Work based on fresh PB and BM samples from MDS patients confirmed the secretion of these 2 cytokines by MDSCs, but interestingly, this secretion was higher in PMN-MDSCs than in M-MDSCs.³¹ In fact, PMN-MDSC subset dominated the MDSC-expansion in high-risk patients. The BM homing chemokine receptors (CXCR4, CX3CR1) were expressed at a higher level on M-MDSCs in high-risk MDS, and there was different expression of CX3CR1 between healthy donors, low-risk MDS and high-risk MDS patients.³¹

The importance of MDSCs in suppression of hemopoiesis in MDS has been demonstrated in 2 genetically manipulated animal models; the S100A9 transgenic mice, displaying BM accumulation of MDSC and progressive cytopenia and the *mDia1/miR146*-a double knockout mice, developing age-related inflammatory BM microenvironment and anemia.^{28,32} S100A8/A9 activation of MDSC is through the NF-κB signaling pathway; therefore, we may hypothesize that by targeting this pathway we could reduce MDSCs levels.³³

Drugs widely used for MDS have lately been shown to affect T-cell polarization, which may suggest effects on MDSCs activity. Azacitidine, the drug of choice in high-risk MDS, has been shown to affect T-cell polarization in the Th17/Treg-axis in high-risk MDS and to influence levels of BM CD57⁺ T-cells, CD57⁺ T-cell degranulation and CD34⁺ BM cell directed cytotoxicity.^{34,35} Specific MDSC-targeting in MDS has so far been aiming at CD33-expressing cells.³⁶ So far, BI 836858 (Fc-engineered anti-CD33 mAb) for antibody-dependent cell-mediated cytotoxicity by NK-cells is currently tested in MDS patients in an ongoing Phase I/II clinical trial (ClinicalTrials.gov Identifier: NCT02240706). Additionally, a clinical trial with CD16/IL-15/CD33 (161533) tri-specific killer cell engager for the treatment of CD33-expressing myeloid malignancies, including high-risk MDS, is not yet recruiting (NCT03214666). Overall, the implication and therapeutic targeting of MDSCs in MDS is an interesting, open field of research.

Lymphomas

Different mice models have been used to study MDSC biology in lymphomas. For example, M-MDSC and PMN-MDSCs from EL4 and EG7 lymphoma models display immunosuppressive capacity associated with increased production of NO and nitrotyrosine (M-MDSCs) and ROS (PMN-MDSCs).^{37,38} Furthermore, MDSCs from A20 B-cell lymphoma model, operate as tolerogenic antigen presenting cells capable of antigen uptake and presentation to tumor-specific Tregs.³⁹ In humans, the number of circulating MDSCs has been correlated with poor prognosis in

diffuse large B-cell lymphoma (DLBCL),^{40,41} indolent lymphoma,⁴² chronic lymphocytic leukemia,^{43,44} and Hodgkin lymphoma (HL).^{40,45} However, only few of the suppressive mechanisms involved in MDSC biology in these disease entities have been elucidated.⁴⁶ In DLBCLs, an increase of immunosuppressive PMN-MDSC numbers expressing arginase-1 has been noticed, however correlation with clinical outcome was not been documented in all studies.^{40,41,47} Similarly, increased numbers of M-MDSCs (CD14⁺HLA-DR^{low}) have been detected in PB from DLBCL patients in various studies.^{41,42,48,49} M-MDSCs from DLBCL patients have been found to overexpress genes involved in MDSC biology such as IL4-R, IL6-R, RELB, STAT3, NFkB, CEBP β , AIM2, TNFR2, and NOX2. Additionally, the T-cell suppressive effect of MDSCs was mediated by a release of IL-10 and S100A12 and an increase in PD-L1 expression.⁴¹ Increased circulating PMN-MDSC (CD66b⁺CD33^{dim}HLA-DR⁻) numbers compared to healthy donors with elevated arginase-1 activity has been observed in a cohort of 31 patients with indolent lymphomas⁴⁰ whereas increased M-MDSC (CD14⁺HLA-DR^{low}) numbers have been detected in another cohort of 22 patients with indolent lymphomas.⁴² Increased PMN-MDSC and M-MDSC numbers and arginase-1 activity have been also identified in PB of HL patients.^{40,45} As regards to T-cell lymphomas, even less is known about the potential role of MDSCs. Patients with mycosis fungoides and Sézary syndrome with stage IB and above have been shown to display increased production of ROS by MDSCs compared to patients with stage IA or healthy controls, despite the normal MDSC numbers and this abnormality was reversed following anti-CD25 denileukin difitox or IFN- α 2b treatment.⁵⁰ Collectively, all the above studies have pointed out the possibility of targeting MDSCs in future therapeutic trials with lymphoma patients by controlling their expansion and/or blocking their immunosuppressive functions.

Multiple myeloma

Multiple myeloma (MM) is a B-cell malignancy characterized by expansion of monoclonal plasma cells preferentially in the BM and the accumulation of monoclonal immunoglobulins in the PB. It is now widely accepted that the BM microenvironment displays a prominent role in pathophysiology of the disease by providing a protective niche to the plasma cells that promotes the immune-escape, drug-resistance, and angiogenesis.⁵¹ An interactive crosstalk between the malignant cells and the BM microenvironment is also responsible for many clinical characteristics of the disease such as the osteolytic lesions, anemia and immunosuppression.⁵¹ According to recent studies, MDSCs are involved in the pathogenesis and progression of MM.^{52–54} Experiments in 5T2 and 5T33MM mice models of MM have shown that the malignant plasma cells can induce the generation and survival of both PMN-MDSCs and M-MDSCs that accumulate in the BM in early stages and in PB at later stages, and display T-cell immunosuppressive activity, through production of NOS, arginase-1 and IL-10, which is highest among M-MDSCs.^{55,56} In the DP42 MM mouse model, however, a more prominent role of the BM PMN-MDSC population was demonstrated for the induction of plasma cell growth and chemoresistance.⁵⁷ The malignant cells secrete factors such as IL-6, GM-CSF, VEGF, IL-1b and exosomes leading to the activation of STAT3 and STAT1 pathways, increase expression of Bcl-xL and Mcl-1 proteins and release of NO enhancing finally the BM angiogenesis as well as the survival and suppressive activity of MDSCs.^{55,58,59} These

effects can be further potentiated by the MSCs in MM BM microenvironment.^{60,61} Using the 5TGM1 mouse model it has also been shown that tumor-induced MDSCs, in addition to their immunosuppressive effect, can be differentiated into mature and functional osteoclasts contributing therefore to the bone destruction associated with the disease.⁶² The importance of MDSCs in the development of MM was demonstrated in the S1009 knockout transgenic mice which display defective response to cancer and delay in the development of MM following inoculation of MM cells which is reversed following adoptive transfer of MDSCs.⁶³ In humans, early studies have shown that MDSCs isolated from the PB of patients with MM display a T-cell inhibitory effect which can be abrogated by drugs inhibiting arginase-1 and iNOS activity.⁶⁴ Similar to mice models, increased number of PMN-MDSCs with immunosuppressive properties has been reported in the BM and PB of patients with MM at diagnosis and relapse compared to healthy subjects.^{63,65,66} The frequency of PMN-MDSCs has been shown to correlate with the disease activity and it is higher in MM patients compared to patients with monoclonal gammopathy of undetermined significance (MGUS) suggesting that these cells can be used as markers of disease activity and progression.^{65–67} Contradictory results have been published so far regarding M-MDSC numbers and function in patients with MM. Increased numbers of M-MDSCs have been reported in BM and PB of newly diagnosed and relapsed MM patients compared to patients in remission or healthy donors suggesting their potential consideration as prognostic predictors of disease activity⁶⁸ whereas other studies have not identified such differences.^{63,65–67} Discrepancies may be due to different flow-cytometric strategies and different quantitative and qualitative characteristics of patient cohorts.

In summary, all available evidence suggests that MDSCs are increased in the patients with MM and participate in the pathophysiology of the disease by inducing the survival and proliferation of malignant plasma cells both directly and indirectly through their immunosuppressive effects. Therefore, MDSCs can become therapeutic targets for MM. It has been shown that the immunomodulatory drug lenalidomide and the proteasome inhibitor bortezomib are able to downregulate molecules produced by MDSCs in MM; however, they cannot abrogate the number or immunosuppressive function of MDSCs.⁶⁶ These observations emphasize the importance of developing novel agents to overcome the immunosuppressive effects of MDSCs in MM patients.

Immune-mediated cytopenias

Immune thrombocytopenia (ITP) is a disease entity characterized by low platelet count due to antiplatelet autoantibodies, abnormal effector T-cell activation and inappropriate platelet production in the BM.⁶⁹ Recent evidence suggests that MDSCs have a role in the pathophysiology of the disease but contradictory results have published thus far on the frequency and function of MDSCs at diagnosis probably due to different flow-cytometry strategies, that is, whole blood or PBMCs.^{70–72} Circulating MDSCs in ITP patients increase following immunosuppressive treatment with high dose dexamethasone (DXM) and MDSC numbers correlate with platelet recovery suggesting that PB MDSCs could be used as markers of response to therapy.^{70–72} It has also been shown that PB and splenic MDSCs in ITP patients display impaired immunosuppressive function contributing possibly to the pathogenesis of the disease and that DXM

treatment improves the immunomodulatory properties of MDSCs including the production of suppressive cytokines and their T-cell suppressive effects.⁷⁰ The effect of DXM on MDSCs was found to correlate with the transcription factor Ets1 both in ITP patients and a murine model of ITP generated following transfer of splenocytes from CD61 knockout mice immunized with CD61⁺ platelets into severe combined immunodeficient mouse recipients.⁷⁰ Interestingly, adoptive cell transfer with MDSCs alleviated thrombocytopenia and resulted in higher survival rate in the ITP murine model.⁷⁰ Treatment with intravenous immunoglobulin (IVIG) has been reported to increase the number of MDSCs in spleen cell cultures from ITP patients indicating that, in addition to blocking the macrophage Fc receptors, IVIG may ameliorate ITP by increasing MDSC populations similar to DXM.⁷³ The findings provide novel insights linking MDSCs with the pathogenesis, disease activity and management of ITP that need further investigation in the clinic.

Chronic idiopathic neutropenia (CIN) is another immune-mediated disorder characterized by prolonged, unexplained reduction in the number of PMN associated in the majority of patients with the presence of activated T-lymphocytes with myelosuppressive properties that induce the apoptotic death of the granulocytic progenitor cells.⁷⁴ Preliminary data on the role of MDSCs have shown low frequency of PB PMN-MDSCs and M-MDSCs in CIN patients and this decrease might contribute to the aberrant T-cell activation and sustained chronic inflammation in CIN, a hypothesis that is currently under investigation.⁷⁵

Aplastic anemia is the prototype of T-cell mediated BM failure syndrome and the potential implication of MDSCs in the abnormal T-cell responses associated with the disease remains an open field for research. In a mouse model of acquired aplastic anemia following deletion of the TGF β -activated kinase-1 gene in hemopoietic cells, the BM failure was significantly progressed following inactivation of TNF α signaling and was associated with increased capacity of macrophages to prime T-helper type I cell development and reduced ability of MDSCs to suppress T-cell proliferation.⁷⁶

Graft versus host disease

Allo-HSCT represents the only curative treatment for a number of hematologic malignancies. The beneficial effect of the treatment is regularly implicated by the immunological attack of the recipient tissues, an effect known as graft-versus-host disease (GvHD) which is associated with significant morbidity and mortality.⁷⁷ Based on their immunosuppressive properties, there is an increasing interest in exploring the possible implication of MDSCs in the development of GvHD and their potential effect on the treatment and patients' clinical outcome.^{78,79} Studies have shown that PMN-MDSCs and M-MDSCs are increased in the PB during G-CSF stem-cell mobilization in human donors⁸⁰ and that the MDSC content of the graft correlates inversely with the risk of acute GVHD risk in patients receiving allogeneic, G-CSF mobilized, PB stem cells.^{81,82} Results from a recent study also showed that accumulation of MDSCs in the graft and in PB during engraftment results in successful control of severe acute GVHD and long-term survival without any influence on the risk of disease recurrence after allo-HSCT.⁸³ In accordance with the clinical data are results from murine models demonstrating that the adoptive transfer of donor MDSCs in fully MHC-mismatched allo-HSCT recipients can result in successful control of GvHD without compromising the graft versus tumor effects.^{84,85}

Although there are no currently clinical trials using MDSC infusions in GvHD patients, the experimental data from animal models and observations from patients undergoing allo-HSCT indicate that MDSCs represent a promising therapeutic tool for the prevention and therapy of GvHD in the clinic.⁸⁶ Certainly, studies evaluating large patient cohorts and long observational periods are required to clarify the beneficial effects of MDSCs in patients receiving allo-HSCT versus potential risks from infections or immunosuppression.

Discussion

In recent years, there has been an increasing interest in the investigation of the contribution of MDSCs in the pathogenesis/pathophysiology of hematologic diseases. Although different protocols and strategies have been used for MDSC investigation and characterization in hematologic diseases, there is conclusive evidence suggesting that similar to their role in cancer induction and progression, MDSCs have a decisive role in hematologic malignancies by suppressing the immune reactions against the malignant cells through previously described mechanisms^{10,11} (Table 1). But also, decreased number and defective function of MDSCs may have a contributing role in the hematologic diseases other than malignancies such as immune-mediated cytopenias including ITP or CIN by augmenting the T-cell mediated platelet or neutrophil destruction.^{70,75} Apparently, MDSCs represent regulatory components of the immune system with critical role in malignant and immune disorders of hemopoiesis.

A particular interest for the implication of MDSCs in hematologic diseases originates from the fact that these cells derive from the hemopoietic stem cells which are primarily affected in a number of myeloid malignancies such as MDS, MPN, and acute leukemias. Although MDSCs may be part of the malignant clone, this is not the case in all circumstances²⁸; definitely, however, they exert systemic immune suppressive effects and may also contribute to a permissive BM microenvironment where the malignant cells can survive and proliferate by evading host immune-surveillance and antitumor therapies.¹¹ In parallel, the malignant cells secrete cytokines, chemokines and growth factors that may sustain and expand MDSCs in a vicious cycle that favors the malignant cell growth and expansion. In lymphoid malignancies, the malignant cells originate from progenitor/precursor or mature cells of the lymphoid system; therefore, any implication of MDSCs in disease pathophysiology, progression and outcome is mediated through their immune-regulatory effects rather than the participation in the malignant population.³⁹⁻⁴⁸

Apart from the current interest in exploring the reserves, distribution and function of MDSC in hematologic diseases and homogenization of the protocols and strategies for their study, there is also an emerging interest in the potential of developing novel therapeutic strategies targeting MDSCs. Interestingly, a number of therapies currently used for hematologic malignancies have been reported to impact on the number and function of MDSCs and have been extensively reviewed elsewhere.^{10,11} For example, all-trans retinoic acid (ATRA) has been shown to induce the differentiation of MDSCs in mice models and patients with solid tumors resulting in reduction of the number and the immune-suppressive effects of MDSCs⁸⁷⁻⁹⁰; its potential effect on MDSCs and consequences in patients with acute promyelocytic leukemia remains to be studied. The pyrimidine nucleoside analog Gemcitabine has been reported to reduce the number of MDSCs inducing therefore an antitumor immunity in mice

Table 1

Summary of Representative Studies Investigating the of MDSCs and Their Subpopulations in Different Hematologic Diseases and Their Effects on Disease Outcome

Disease	Patients' Origin	Number of Patients/Controls (if Available)	Definition of MDSCs*	Source	Observation/Outcome	Refs.
CML	Sweden	36 patients/18 controls	CD11b ⁺ CD33 ⁺ CD14 ⁻	PB	PB of both high- and low-risk (Sokal score) patients showed higher % of CD34 ⁺ cells in the subpopulation of CD11b ⁺ CD33 ⁺ CD14 ⁻ and higher expression of PD-L1 in CD11b ⁺ cells than healthy controls. PB of high-risk patients contains higher numbers of CD34 ⁺ PD-L1 ⁺ cells than healthy controls	14
CML	Italy	19 patients at diagnosis and 18 patients during therapy (13 of whom were also collected at diagnosis)/20 controls	MDSCs: CD11b ⁺ CD33 ⁺ CD14 ⁻ HLADR ⁻ ; G-MDSCs: CD11b ⁺ CD33 ⁺ CD14 ⁻ HLADR ⁻ ; M-MDSCs: CD14 ⁺ HLADR ⁻	PB	Patients at diagnosis have higher proportions of G- and M-MDSCs than healthy donors and patients after imatinib treatment: G-MDSCs of patients at diagnosis produce higher levels of arginase-1 and have a higher suppressive effect on T-cell proliferation <i>in vitro</i> than G-MDSCs from donors and patients after therapy	15
CML	Italy	59 patients; available clinical characteristics in 42; 13 treated with dasatinib	G-MDSCs: CD11b ⁺ CD33 ⁺ CD14 ⁻ HLA-DR ⁻ ; M-MDSCs: CD14 ⁺ HLA-DR ⁻	PB	CML patients have higher levels of both G-MDSCs and M-MDSCs than healthy controls; patients with higher numbers of M-MDSC do not exhibit MMR after treatment with dasatinib	16
CML	Australia	78 patients; different stages of disease and treatment	MDSCs: HLA-DR ⁻ Lin ⁻ CD11b ⁺ CD33 ⁺ ; G-MDSCs: HLA-DR ⁻ Lin ⁻ CD11b ⁺ CD33 ⁺ CD66b ⁺ CD15 ⁺ ; M-MDSCs: HLA-DR ⁻ Lin ⁻ CD11b ⁺ CD33 ⁺ CD66b ⁺ CD14 ⁺	PB	G-MDSCs are increased in CML patients at diagnosis in comparison with pre-MMR, MMR, MR and TR; M-MDSCs are also increased at diagnosis in comparison with healthy donors and patients in MR and TR	17
CML	Italy	30 patients, 20 controls; BM CML = 10, controls = 8	G-MDSCs: CD11b ⁺ CD33 ⁺ CD15 ⁺ HLA-DR ⁻ CD66b ⁺	PB, BM	Patients have higher levels of G-MDSCs than healthy controls; G-MDSCs from CML patients have higher immunosuppressive activity (inhibition of T-cell proliferation) than G-MDSCs from healthy donors; higher expression of immunomodulatory mRNAs by CML-MDSCs and -MDCs	18
MPN	USA	55 patients; different subtypes of MPN/23 controls	CD11b ⁺ CD33 ⁺ CD14 ⁻	PB	MPN patients have higher level of MDSCs than healthy controls; MDSCs from MPN patients exhibit higher suppression of T-cell proliferation and express higher level of arginase-1 mRNA than MDSCs from healthy controls	20
AML	China	27 patients/12 controls (anemia or hyperplastic patients)	CD11b ⁺ CD33 ⁺ HLA-DR ^{low/-}	BM	Increased level of MDSCs in AML patients in comparison with controls; MDSC levels correlate with plasma D-dimers; frequency of MDSCs decreases after AML treatment, but is higher in patients with MRD	21
AML	Israel, USA ² —data not given in the main body article	Numbers not given	M-MDSCs: CD11b ⁺ HLA-DR ⁻ CD14 ⁺ CD33 ⁺ CD15 ⁻ ; G-MDSCs: CD11b ⁺ HLA-DR ⁻ CD14 ⁺ CD33 ⁺ CD15 ⁺	PB	Higher levels of both M-MDSCs and G-MDSCs in AML patients than in healthy controls; <i>in vitro</i> experiments with AML cell lines MOLN-14 and THP-1 that release tumor-derived extracellular vesicles (EV); treatment of PBMCs with EV increases MDSCs	22
B-ALL	China	43 patients before treatment (after treatment 35 in remission, 8 not)	G-MDSCs: CD45 ⁺ CD19 ⁻ HLA-DR ⁻ CD11b ⁺ CD33 ⁺ CD15 ⁺ ; M-MDSCs: CD45 ⁺ CD19 ⁻ HLA-DR ⁻ CD11b ⁺ CD33 ⁺ CD14 ⁺	PB, BM	G-MDSCs higher both in PB and BM in patients before therapy than in healthy controls and in patients in remission; no significant difference in patients without remission; no differences observed in M-MDSCs	23
B-ALL	Egypt	43 patients	MDSCs: Lin ⁻ HLA-DR ⁻ CD33 ⁺ CD11b ⁺	PB	Patients at diagnosis have higher levels of MDSCs than healthy donors; during chemotherapy MDSCs numbers increased	24
MDS	Netherlands	12 MDS patients/8 non-MDS cancer patients (4 breast cancer and 4 lymphoma)/8 controls	Lin ⁻ HLA-DR ⁻ CD33 ⁺	BM	MDS patients have higher % of MDSCs than both non-MDS patients and controls; <i>in vitro</i> : MDSCs have a direct suppressive effect on erythroid and myeloid progenitor cell development; proliferation of MDSCs is driven by the S100A9/CD33 pathway	28
MDS	Norway, UK	42 pretreatment patients, 23 from them BM sample/12 controls PB, 3 of them BM	MDSCs: Lin ⁻ CD33 ⁺ CD11b ⁺ ; G-MDSCs: Lin ⁻ CD33 ⁺ CD11b ⁺ CD15 ⁺ ; M-MDSCs: Lin ⁻ CD33 ⁺ CD11b ⁺ CD14 ⁺	PB, BM	MDSCs are increased in PB of patients than in healthy donors; MDSCs/G-MDSCs are more in patients with intermediate, high and very high risk than in patients with very low and low risk; M-MDSCs expression of CX3CR1 is higher in PB from intermediate and high-risk patients compared to BM	31
MDS	USA	40 patients/controls from blood bank	Not available	BM	Ex vivo: BM cells cocultured with Fc-engineered CD33 antibody BI 836858 resulted in blockage CD33-mediated IL-10 expression both in MDS patients and in healthy donors	36
CLL	USA	29 patients/15 controls	CD14 ⁺ HLA-DR ^{low/-}	PB	Patients had higher number of MDSCs than healthy controls; numbers of MDSCs decreased with remission	43
CLL	Germany	79 untreated patients/61 Binet stage A, 6 stage B, 12 newly diagnosed stage C/44 patients/40 healthy donors; analysis of frequency of MDSCs; in 4 patients suppressive activities of MDSCs were tested	CD14 ⁺ HLA-DR ^{low}	PB	Patients have higher numbers of MDSCs than healthy donors. <i>ex vivo</i> and <i>in vitro</i> : IDO ^{high} /MDSCs from patients suppress T-cells and promote Treg induction; CLL cells induce conversion of monocytes into MDSCs	44
B-cell NHL (DLBCL and other lymphomas)	USA	40 patients (4 newly diagnosed, 36 relapsed)/27 controls	CD14 ⁺ HLA-DR ^{low/-}	PB	PBMCs of patients showed lower recall response to influenza than controls—partly mediated by monocytes; patients have higher numbers of CD14 ⁺ HLA-DR ^{low/-} subpopulation than controls; the number of CD14 ⁺ HLA-DR ^{low/-} is associated with more aggressive disease	42

(continued)

Table 1
(continued).

Disease	Patients' Origin	Number of Patients/Controls (if Available)	Definition of MDSCs [†]	Source	Observation/Outcome	Refs.
HL, B-cell NHL	Italy	124 patients (117 analyzed for MDSCs and outcome)/48 controls	MDSCs: CD45 ⁺ CD66b ⁺ CD33 ^{dim} HLA-DR ⁻ ; LDNs (mature low-density neutrophils) subpopulation within MDSCs expressing CD11b ⁺ CD16 ⁺	PB	Higher proportion of MDSCs in lymphoma patients than in healthy donors; patients with higher median numbers of MDSCs than patient have worse FFDP (freedom from disease progression)	40
HL	Italy	60 newly diagnosed HL patients/25 controls	immature MDSCs: CD11b ⁺ CD33 ⁺ CD14 ⁻ CD34 ⁺ HLA-DR ⁻ ; G-MDSCs: CD11b ⁺ CD33 ⁺ CD14 ⁻ HLA-DR ⁻ Lin ⁻ ; M-MDSCs: CD14 ⁺ HLA-DR ^{low}	PB	Patients have higher numbers of all subtypes of MDSCs than healthy controls; less CD34 ⁺ MDSCs associated with better outcome of chemotherapy	45
DLBCL	Israel	109 patients; PB from 23 patients, 15 controls	M-MDSCs: CD45 ⁺ CD14 ⁺ HLA-DR ^{low}	PB	Newly diagnosed patients have higher numbers of M-MDSCs than patients with complete remission after treatment and healthy controls	48
DLBCL	France	Cohort 1: 76 patients/87 controls, cohort 2: 66 patients/45 MDSCs controls	M-MDSCs: CD14 ⁺ HLA-DR ^{low} ; G-MDSCs: Lin ⁻ CD123 ^{low} HLA-DR ⁻ CD33 ⁺ CD11b ⁻	PB	Both M-MDSCs and G-MDSCs were higher in proportion in patients than in healthy donors; M-MDSCs were increased in high risk than in low-risk patients; M-MDSCs suppressive activity on T-cell proliferation is independent of arginase-1 and IDO and is linked with IL-10, PDL-1 and S100A12	41
DLBCL	China	144 patients	M-MDSCs: CD14 ⁺ HLA-DR ^{low} , monocytes; markers not given	PB	M-MDSCs decrease after chemotherapy irrespective of the outcome; M-MDSCs > 8% before treatment are associated with better prognosis	49
MF and SS	USA	77 patients, 26 SS and 51 MF without PB involvement/7 controls	CD33 ⁺ CD11b ⁺ CD86 ⁺ CD14 ⁻ HLA-DR ⁻	PB	MDSCs proportion is lower in MF patients in stage ≥IB than in healthy controls; MDSCs of MF patients in stage ≥IB produce more ROS than MDSCs of other patients and healthy controls; treatment with IFN-α2b (7 patients) resulted in no change of MDSCs frequencies, responders (4 patients) had decreased serum arginase-1 and intracellular ROS in MDSCs	50
MM	China	Numbers not given	CD11b ⁺ CD142 ⁺ CD33 ⁺	BM	In vitro: MSCs from patients promote MDSCs proliferation more than MSCs from healthy donors; MSCs stimulate production of arginase-1 and NOS2 by MDSCs	61
MM	USA	BM: 15 patients/6 controls; PB: 11 patients/10 controls	MDSCs: CD11b ⁺ CD14 ⁻ CD33 ⁺ ; PMN-MDSCs: CD11b ⁺ CD14 ⁻ CD33 ⁺ CD15 ⁺ ; M-MDSCs: CD11b ⁺ CD14 ⁻ CD33 ⁺ CD15 ⁻ or CD11b ⁺ CD14 ⁻ HLA-DR ^{-low}	BM, PB	Patients display higher % of MDSCs and PMN-MDSCs in BM and PB than healthy donors; same % of M-MDSCs was observed in PB and BM, but M-MDSCs from BM of patients exhibit higher suppressive activity of T-cells	63
MM, MGUS	Italy	45 MM patients (30 newly diagnosed, 15 relapsed), 30 MGUS/30 controls	G-MDSCs: CD11b ⁺ CD15 ⁺ CD14 ⁻ HLA-DR ⁻	PB	Patients with MM have higher % of G-MDSCs than MGUS patients and healthy donors; in vitro: only MM G-MDSCs can suppress autologous T-cell proliferation; MM-MSC-educated G-MDSCs can digest bone matrix	65
MM	USA	17 patients (4 newly diagnosed, 4 relapsed, 9 relapsed/refractory)/5 controls	MDSCs: CD11b ⁺ CD14 ⁻ CD33 ⁺ HLA-DR ^{-low} and/or CD11b ⁺ CD14 ⁻ HLA-DR ^{-low} CD15 ⁺	PB, BM	Patients have increased MDSCs both in PB and BM compared to healthy donors; frequency of MDSCs increases in relapsed/refractory patients; MDSCs from PB and BM patients suppress T-cell proliferation and promote tumor growth	66
MM	Australia	35 patients (10 progressive disease, 25 stable disease)/11 controls	G-MDSCs: CD33 ⁺ CD11b ⁺ HLA-DR ^{-low} CD14 ⁻ CD15 ⁺ ; M-MDSCs: CD33 ⁺ CD11b ⁺ HLA-DR ^{-low} CD14 ⁻ CD15 ⁻	PB, BM	Patients have higher % and absolute numbers of G-MDSCs than healthy donors; patients with progressive disease have higher numbers of G-MDSCs than patients with stable disease; G-MDSCs both from patients and healthy donors did not differ in T cell inhibition	67
MM	China	93 patients (41 newly diagnosed, 12 relapsed, 40 remission)/30 controls (PB only)	M-MDSCs: CD14 ⁺ HLA-DR ⁻	PB, BM	Patients have higher % of M-MDSCs than healthy donors; higher % of M-MDSCs in newly diagnosed and relapsed patients than in patients in remission both in PB and BM	68
ITP	China	PB: 21 patients/18 controls; spleen 5 patients, 5 controls	MDSCs: CD11b ⁺ CD33 ⁺ HLA-DR ^{low}	PB, spleen	PB: patients display lower MDSCs, lower arginase 1, higher iNOS than healthy donors; treatment with high dose DXM results in expansion of MDSCs	70
ITP	China	25 patients/10 controls	MDSCs: CD11b ⁺ CD33 ⁺ HLA-DR ⁻	PB	Patients have lower MDSCs, platelets and Tregs than healthy donors; treatment with DXM leads to increase of MDSCs and platelets, but not Tregs	71
ITP	China	33 patients/18 controls	MDSCs: CD11b ⁺ CD33 ⁺ HLA-DR ⁻	PB	Patients have higher numbers of MDSCs than healthy donors; treatment with high dose DXM results in increase of MDSCs and M-2 like macrophages (CD68 ⁺ CD163 ⁺) in patients with complete response and decrease of MDSCs in patients with partial and no response	72
ITP	USA	7 patients/7 controls—trauma patients	MDSCs: CD11b ⁺ CD33 ⁺ HLA-DR ⁻	Spleen	In vitro: treatment of spleen cells with intravenous immunoglobulin led to higher increase of MDSCs in ITP patients than in trauma controls	73
CIN	Greece	34 patients/23 controls	PMN-MDSCs: CD11b ⁺ CD33 ⁺ HLA-DR ^{low} CD15 ⁺ ; M-MDSCs: CD11b ⁺ CD33 ⁺ HLA-DR ^{low} CD14 ⁺	PB	Patients have significantly decreased proportion of M-MDSCs but not PMN-MDSCs than healthy donors	75
allo-HSCT	Belgium	6 G-CSF-treated PBSC donors/3 controls	MDSCs: Lin ⁻ HLA-DR ⁻ CD11b ⁺ ; M-MDSCs: Lin ⁻ HLA-DR ⁻ CD11b ⁺ CD33 ^{high} CD14 ^{high} CD15 ⁺ ; G-MDSCs: Lin ⁻ HLA-DR ⁻ CD11b ⁺ CD33 ^{high} CD14 ^{low} CD15 ^{high}	PB	Increase of MDSCs in G-CSF-treated donors in comparison with controls; in vitro: both M-MDSCs and G-MDSCs from donors suppress T-cell proliferation, effect of M-MDSCs more pronounced.	80
aGVHD	Italy	60 allo-HSCT patients/60 donors/60 controls	M-MDSCs: Lin ^{low} HLA-DR ⁻ CD11b ⁺ CD33 ⁺ CD14 ⁺	PB	G-CSF treated donors have higher % of M-MDSCs than controls; in vitro: M-MDSCs from donors suppress T-cell proliferation; aGVHD in patients inversely correlated with % of M-MDSCs in the PBSC graft	81

(continued)

Table 1
(continued).

Disease	Patients' Origin	Number of Patients/Controls (if Available)	Definition of MDSCs [†]	Source	Observation/Outcome	Refs.
aGVHD/cGVHD	China	62 allo-HSCT patients (leukemia, MDS-refractory anemia)/20 donors	M-MDSCs: SSC ^{low} CD11b ⁺ CD33 ⁺ HLA-DR ⁻ Lin ⁻ CD15 ^{dim} CD16 ⁻ CD14 ⁺ ; G-MDSCs: SSC ^{high} CD11b ⁺ CD33 ^{dim} CD15 ⁺ HLA-DR ⁻ Lin ⁻ ; Promyelocytic(P)-MDSCs: CD33 ⁺ CD11b ^{dim} CD16 ⁻ Lin ⁻	BM, PB	Treatment of donors with G-CSF led to increase of M/G/P-MDSCs in both BM and PB; early reconstitution of M-MDSCs in PB of patients was associated with a low risk of aGVHD and cGVHD	82
aGVHD	China	8 ALL, 15 AML, 5 MDS and 2 CML patients undergoing allo-HSCT	MDSCs: CD14 ⁺ CD11b ⁺ CD11c ⁺ CD13 ⁺ CD15 ⁺ CD33 ⁺ CD62L ⁺ HLA-DR ^{-/low} (authors call them M-MDSC, but CD15 is also present)	PB	Patients that do not develop aGVHD have higher numbers of MDSCs and Tregs in the graft (relationship to body weight) than those that develop aGVHD and healthy controls	83

aGVHD = acute graft versus host disease, ALL = acute lymphoblastic leukemia, Allo-HSCT = allogeneic hematopoietic stem cell transplantation, AML = acute myeloid leukemia, BM = bone marrow, cGVHD = chronic graft versus host disease, CIN = chronic idiopathic neutropenia, CLL = chronic lymphocytic leukemia, CML = chronic myeloid leukemia, DLBCL = diffuse large B-cell lymphoma, DMR = deep molecular response, DXM = dexamethasone, G-CSF = granulocyte-colony stimulating factor, G-MDSCs = granulocytic myeloid-derived suppressor cells, HL = Hodgkin lymphoma, IDO = indoleamine 2,3-dioxygenase, IFN = interferon, IL = interleukin, INHL = indolent B-cell NHL, INOS = inducible nitric oxide synthase, ITP = immune thrombocytopenia, Lin⁻ = CD3-CD14-CD16-CD19-CD20-CD56-(HLA-DR-), MDSCs = myeloid-derived suppressor cells, MF = mycosis fungoides, MGUS = monoclonal gammopathy of undetermined significance, MM = multiple myeloma, M-MDSCs = monocytic myeloid-derived suppressor cells, MMR = major molecular response, BCR-ABL/≤ 0.1%, MPN = myeloproliferative neoplasms (BCR-ABL) negative, MR = molecular response, BCR-ABL/≤ 0.0032%, MRD = minimal residual disease, MSCs = mesenchymal stromal cells, NHL = non-Hodgkin lymphoma, PB = peripheral blood, PBMCs = peripheral blood mononuclear cells, PBSC = peripheral blood stem cell, PDL-1 = programmed death receptor ligand-1, PMN-MDSCs = polymorphonuclear myeloid-derived suppressor cells, pre-MMR = pre-major molecular response, BCR-ABL/ > 0.1%, ROS = reactive oxygen species, S/S = Sezary syndrome, TR = treatment free remission.

[†]Control samples were obtained from healthy blood donors if not stated otherwise (Ref.²¹).

[‡]The term G-MDSCs has been currently substituted by the term PMN-MDSC. However, in this table we use the terminology of the authors.

models and patients with pancreatic cancer.^{91,92} The N-bisphosphonate zoledronic acid has been reported to decrease MDSCs by downregulating MMP9, among other proteins, in patients with pancreatic cancer.⁹³ The drug has also been shown to inhibit the bone resorption in MM animal models by reducing the osteoclast formation by MDSCs.⁶² It has also been indicated that the anti-CD38 monoclonal antibody Daratumumab currently used for the eradication of plasma cells in MM patients may additionally eliminate patient MDSCs which also express CD38 according to recently reported data.⁹⁴ Therefore, we may speculate that the well-recognized beneficial effect of all the above treatments in patients with hematologic malignancies might be partially related to their effect on the reserves and functional properties of MDSCs, a hypothesis that needs further investigation. On the other hand, a number of novel therapies currently used in hematologic malignancies target pathways in tumor cells that are also involved in the regulation of physiological processes in MDSCs.⁹⁵ Representative examples are the PI3K and Jak/Stat signaling pathways which are therapeutic targets in lymphomas and MPNs as well as key signaling pathways in MDSCs.⁹⁵ The possible effect of these target therapies on MDSCs and the possibility of an additive effect on the therapeutic outcome is an interesting field of research. It has also been shown that epigenetic modulation of genes such as retinoblastoma 1 (Rb1) may alter the reserves and function of MDSCs.⁹⁶ It is therefore interesting to investigate whether epigenetic regulators including the hypomethylating agents widely used in the treatment of MDS/AML, have also an impact on the MDSC component of the BM microenvironment. Even the FLT3 pathway, representing currently a target for patients with AML and advanced systemic mastocytosis,⁹⁷ has been associated with the expansion and function of MDSCs⁹⁸; therefore the potential alterations of MDSCs in patients treated with the FLT3 inhibitor midostaurin remain to be investigated. Beyond the potential effect of existing therapies on the quantitative and qualitative characteristics of MDSCs, the development of novel therapies targeting MDSC-related signaling pathways or surface molecules, such as CD33, is challenging.

Despite the increasing knowledge on the biology of MDSCs, a number of issues related to the generation, expansion, and circulation of these cells and their precise role in the microenvironment of BM and lymphoid tissues in malignant and immune-mediated hematologic disorders undoubtedly need further investigation. The homogenization of the methods for MDSC assessment is also an important issue because there is considerable variability in how MDSCs have been measured and reported in different studies and the lack of uniform protocols can lead to inconsistencies, uncertainties and erroneous conclusions.⁹⁹ Even the standard method, that is, the immunophenotyping, currently used for the measurement of MDSCs in the low density fraction of PBMCs and BMMCs,⁵ needs further improvement because it prevents the accurate quantification of absolute MDSC numbers whereas markers unique for MDSCs have not been identified so far. Therefore, the functional characterization, and specifically the T-cell suppression activity, remains a key assay for MDSC definition (Fig. 2). Recently, guidelines for the standardization and harmonization of the functional assays were published by a working group from EU COST Mye-Euniter consortium (<http://www.mye-euniter.eu>) aiming to diminish variations across laboratories for the study of MDSCs from different diseases and tissue sources.¹⁰⁰

Overall, the better characterization of MDSCs and the elucidation of the molecular and signaling pathways implicated




Figure 2. Algorithm for the characterization of MDSCs in human PB samples or BM aspirates. For the characterization of a candidate cell population as MDSCs, both the specific immunophenotypic characteristics and the immunosuppressive potential of the cells should be determined. The immunosuppressive potential of the cells should preferentially be performed by a functional assay demonstrating their T-cell suppressive capacity. If the candidate MDSC population lacks a T-cell suppressive function, then this potential should indirectly be demonstrated by the biochemical and/or molecular characterization of the cells. The figure depicts representative functional assays and biochemical and molecular characteristics of MDSCs according to recent recommendations.⁵ ARG1=arginase-1, BM=bone marrow, BMMCs=bone marrow mononuclear cells, C/EBP β =CCAAT/enhancer binding protein β , CHOP=C/EBP homologous protein, ELISA=enzyme-linked immunosorbent assay, ELISPOT=enzyme-linked immunospot, e-MDSCs=early MDSCs, IFN γ =interferon γ , IL=interleukin, IRF8=interferon regulatory factor 8, MDSC=myeloid-derived suppressor cells, M-MDSCs=monocytic MDSCs, NOS=nitric oxide synthases, NOX=NADPH=oxidase, PB=peripheral blood, PBMCs=peripheral blood mononuclear cells, PD-L1=programmed death-ligand 1, PGE2=prostaglandin E2, PHA=phytohemagglutinin, PMN-MDSCs=polymorphonuclear MDSCs, PNT=peroxynitrite, RB=retinoblastoma, RNS=reactive nitrogen species, ROR=RAR-related orphan receptors, ROS=reactive oxygen species, STAT=signal transducer and activator of transcription, sXBP=spliced X-box binding protein, TGF=transforming growth factor, VEGF=vascular endothelial growth factor.

in MDSC generation, expansion and function are anticipated to unravel novel pathogenetic mechanisms in normal and abnormal hemopoiesis and may offer novel therapeutic approaches for patients with malignant and immune-mediated hematologic disorders including patients undergoing allo-ASCT.

Acknowledgments

The authors would like to thank all members of the COST Action BM1404 Mye-EUNITER for the fruitful discussions during the consortium meetings that helped to the writing of this review. We also gratefully acknowledge the Action for the financial support to NB and SB for short term scientific mission (STSM) exchanges between their Research Laboratories providing expertise that greatly assisted in the writing process of this paper.

References

- Talmadge JE, Gabrilovich DI. History of myeloid derived suppressor cells (MDSCs) in the macro- and micro-environment of tumour-bearing hosts. *Nat Rev Cancer*. 2013;13:739–752.
- Gabrilovich DI, Bronte V, Chen SH, et al. The terminology issue for myeloid-derived suppressor cells. *Cancer Res*. 2007;67:1425–1425.
- Gabrilovich DI. Myeloid-derived suppressor cells. *Cancer Immunol Res*. 2017;5:3–8.
- Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. *Nat Immunol*. 2018;19:108–119.
- Bronte V, Brandau S, Chen SH, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. *Nat Commun*. 2016;7:1–10.
- Condamine T, Dominguez GA, Youn JI, et al. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. *Sci Immunol*. 2016;1:aaf8943.
- Umansky V, Adema GJ, Baran J, et al. Interactions among myeloid regulatory cells in cancer. *Cancer Immunol Immunother*. 2018.
- Millrud CR, Bergenfelz C, Leandersson K. On the origin of myeloid-derived suppressor cells. *Oncotarget*. 2017;8:3649–3665.
- Zhao Y, Wu T, Shao S, et al. Phenotype, development, and biological function of myeloid-derived suppressor cells. *Oncoimmunology*. 2016;5:e1004983.
- De Veirman K, Van Valckenborgh E, Lahmar Q, et al. Myeloid-derived suppressor cells as therapeutic target in hematological malignancies. *Front Oncol*. 2014;4:1–11.
- Younos IH, Abe F, Talmadge JE. Myeloid-derived suppressor cells: their role in the pathophysiology of hematologic malignancies and potential as therapeutic targets. *Leuk Lymphoma*. 2015;56:2251–2263.
- Vladimirova IL, Sosunova E, Nikolaev A, et al. Mesenchymal stem cells and myeloid derived suppressor cells: common traits in immune regulation. *J Immunol Res*. 2016;2016: 7121580. <http://dx.doi.org/10.1155/2016/7121580>.

13. Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. *Blood Cancer J.* 2018;8:15.
14. Christiansson L, Söderlund S, Svensson E, et al. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. *PLoS ONE.* 2013;8:1–12.
15. Giallongo C, Parrinello N, Tibullo D, et al. Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with Polymorphonuclear Leukocytes (PMNs) in chronic myeloid leukemia patients. *PLoS ONE.* 2014;9:1–13.
16. Giallongo C, Parrinello NL, La Cava P, et al. Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib. *J Cell Mol Med.* 2018;22:1070–1080.
17. Hughes A, Clarkson J, Tang C, et al. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. *Blood.* 2017;129:1166–1176.
18. Giallongo C, Romano A, Parrinello NL, et al. Mesenchymal stem cells (MSC) regulate activation of granulocyte-like myeloid derived suppressor cells (G-MDSC) in chronic myeloid leukemia patients. *PLoS ONE.* 2016;11:1–13.
19. Barosi G. An immune dysregulation in MPN. *Curr Hematol Malig Rep.* 2014;9:331–339.
20. Wang JC, Kundra A, Andrei M, et al. Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm. *Leuk Res.* 2016;43:39–43.
21. Sun H, Li Y, Zhang Z-F, et al. Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia. *Int J Hematol.* 2015;102:579–586.
22. Pyzer AR, Stroopinsky D, Rajabi H, et al. MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. *Blood.* 2017;129:1791–1802.
23. Liu Y-F, Chen Y-Y, He Y-Y, et al. Expansion and activation of granulocytic, myeloid-derived suppressor cells in childhood precursor B cell acute lymphoblastic leukemia. *J Leukoc Biol.* 2017;102:449–458.
24. Salem ML, El-Shanshory MR, Abdou SH, et al. Chemotherapy alters the increased numbers of myeloid-derived suppressor and regulatory T cells in children with acute lymphoblastic leukemia. *Immunopharmacol Immunotoxicol.* 2018;40:158–167.
25. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood.* 2016;127:2391–2406.
26. Kordasti SY, Afzali B, Lim Z, et al. IL-17-producing CD4+ T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. *Br J Haematol.* 2009;145:64–72.
27. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. *Nat Rev Immunol.* 2009;9:162–174.
28. Chen X, Eksioglu EA, Zhou J, et al. Induction of myelodysplasia by myeloid-derived suppressor cells. *J Clin Invest.* 2013;123:4595–4611.
29. Zhao F, Hoechst B, Duffy A, et al. S100A9 a new marker for monocytic human myeloid-derived suppressor cells. *Immunology.* 2012;136:176–183.
30. Sato Y, Goto Y, Narita N, et al. Cancer cells expressing toll-like receptors and the tumor microenvironment. *Cancer Microenviron.* 2009;2:S205–S214.
31. Kittang AO, Kordasti S, Sand KE, et al. Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome. *Oncimmunology.* 2016;5:1–9.
32. Mei Y, Zhao B, Basiorka AA, et al. Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS. *Leukemia.* 2018;32:1023–1033.
33. Sinha P, Okoro C, Foell D, et al. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. *J Immunol.* 2008;181:4666–4675.
34. Sand K, Theorell J, Bruserud Ø, et al. Reduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromes. *Cancer Immunol Immunother.* 2016;65:1135–1147.
35. Bontkes HJ, Ruben JM, Alhan C, et al. Azacitidine differentially affects CD4 pos T-cell polarization in vitro and in vivo in high risk myelodysplastic syndromes. *Leuk Res.* 2012;36:921–930.
36. Eksioglu EA, Chen X, Heider KH, et al. Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody B. *Leukemia.* 2017;31:2172–2180.
37. Movahedi K, Williams M, Bossche J, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. *Blood.* 2012;111:4233–4244.
38. Youn J-I, Nagaraj S, Collazo M, et al. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. *J Immunol.* 2008;181:5791–5802.
39. Serafini P, Mgebroff S, Noonan K, et al. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. *Cancer Res.* 2008;68:5439–5449.
40. Marini O, Spina C, Mimiola E, et al. Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients. *Oncotarget.* 2016;7:27676–27688.
41. Azzaoui I, Uhel F, Rossille D, et al. T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid derived suppressor cells expressing IL-10, PD-L1 and S100A12. *Blood.* 2016;128:1081–1092.
42. Lin Y, Gustafson MP, Bulur PA, et al. Immunosuppressive CD14+HLA-DR^{low} monocytes in B-cell non-Hodgkin lymphoma. *Blood.* 2011;117:872–881.
43. Gustafson MP, Abraham RS, Lin Y, et al. Association of an increased frequency of CD14+ HLA-DR^{low} monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL). *Br J Haematol.* 2012;156:674–676.
44. Jitschin R, Braun M, Büttner M, et al. CLL-cells induce IDOhi CD14+ HLA-DRlo myeloid derived suppressor cells that inhibit T-cell responses and promote TRegs. *Blood.* 2014;124:750–760.
45. Romano A, Parrinello NL, Vetro C, et al. Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy. *Br J Haematol.* 2015;168:689–700.
46. Betsch A, Rutgeerts O, Fevery S, et al. Myeloid-derived suppressor cells in lymphoma: the good, the bad and the ugly. *Blood Rev.* 2018;32:490–498.
47. Gustafson MP, Lin Y, Maas ML, et al. A method for identification and analysis of non-overlapping myeloid immunophenotypes in humans. *PLoS ONE.* 2015;10:1–19.
48. Tadmor T, Fell R, Polliack A, et al. Absolute monocytosis at diagnosis correlates with survival in diffuse large B-cell lymphoma-possible link with monocytic myeloid-derived suppressor cells. *Hematol Oncol.* 2013;31:325–331.
49. Wu C, Wu X, Liu X, et al. Prognostic significance of monocytes and monocytic myeloid-derived suppressor cells in diffuse large B-cell lymphoma treated with R-CHOP. *Cell Physiol Biochem.* 2016;39:521–530.
50. Geskin LJ, Akilov OE, Kwon S, et al. Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome. *Cancer Immunol Immunother.* 2018;67:423–434.
51. Raab MS, Podar K, Breitkreutz I, et al. Multiple myeloma. *Lancet.* 2009;374:324–339.
52. Botta C, Gullà A, Correale P, et al. Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities. *Front Oncol.* 2014;4:1–12.
53. Yazdani Y, Mohammadnia-Afrouzi M, Yousefi M, et al. Myeloid-derived suppressor cells in B cell malignancies. *Tumor Biol.* 2015;36:7339–7353.
54. Malek E, de Lima M, Letterio JJ, et al. Myeloid-derived suppressor cells: the green light for myeloma immune escape. *Blood Rev.* 2016;30:341–348.
55. De Veirman K, Van Ginderachter JA, Lub S, et al. Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells. *Oncotarget.* 2015;6:10532–10547.
56. Van Valckenborgh E, Schoupe E, Movahedi K, et al. Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow. *Leukemia.* 2012;26:2424–2428.
57. Ramachandran IR, Condamine T, Lin C, et al. Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy. *Cancer Lett.* 2016;371:117–124.
58. Wang J, De Veirman K, Faict S, et al. Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression. *J Pathol.* 2016;239:162–173.
59. Binsfeld M, Muller J, Lamour V, et al. Granulocytic myeloid-derived suppressor cells angiogenesis in the context of multiple myeloma

- promote angiogenesis in the context of multiple myeloma. *Oncotarget*. 2016;7:37931–37943.
60. Wang J, De Veirman K, De Beule N, et al. The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells. *Oncotarget*. 2015;6:43992–44004.
 61. Xu Y, Zhang X, Liu H, et al. Mesenchymal stromal cells enhance the suppressive effects of myeloid-derived suppressor cells of multiple myeloma. *Leuk Lymphoma*. 2017;58:2668–2676.
 62. Zhuang J, Zhang J, Lwin ST, et al. Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+ myeloid-derived suppressor cells. *PLoS ONE*. 2012;7:e48871.
 63. Ramachandran I, Martner A, Pisklakova A, et al. Myeloid derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. *J Immunol*. 2013;190:3815–3823.
 64. Serafini P, Meckel K, Kelso M, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. *J Exp Med*. 2006;203:2691–2702.
 65. Giallongo C, Tibullo D, Parrinello NL, et al. Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC). *Oncotarget*. 2016;7:85764–85775.
 66. Gorgun GT, Whitehill G, Anderson JL, et al. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. *Blood*. 2013;121:2975–2987.
 67. Favalaro J, Liyadipitiya T, Brown R, et al. Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma. *Leuk Lymphoma*. 2014;55:2893–2900.
 68. Wang Z, Zhang L, Wang H, et al. Tumor-induced CD14+HLA-DR-/low myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients. *Cancer Immunol Immunother*. 2015;64:389–399.
 69. Karpatkin S. Autoimmune (idiopathic) thrombocytopenic purpura. *Lancet*. 1997;349:1531–1536.
 70. Hou Y, Feng Q, Xu M, et al. High-dose dexamethasone corrects impaired myeloid-derived suppressor cell function via Ets1 in immune thrombocytopenia. *Blood*. 2016;127:1587–1597.
 71. Zhou J, Zhou Y, Wen J, et al. Circulating myeloid-derived suppressor cells predict disease activity and treatment response in patients with immune thrombocytopenia. *Brazilian J Med Biol Res*. 2017;50:2–7.
 72. Shao X, Wu B, Cheng L, et al. Distinct alterations of CD68+CD163+ M2-like macrophages and myeloid-derived suppressor cells in newly diagnosed primary immune thrombocytopenia with or without CR after high-dose dexamethasone treatment. *J Transl Med*. 2018;16:1–11.
 73. Aslam R, Burack WR, Segel GB, et al. Intravenous immunoglobulin treatment of spleen cells from patients with immune thrombocytopenia significantly increases the percentage of myeloid-derived suppressor cells. *Br J Haematol*. 2018;181:262–264.
 74. Papadaki HA, Stamatopoulos K, Damianaki A, et al. Activated T-lymphocytes with myelosuppressive properties in patients with chronic idiopathic neutropenia. *Br J Haematol*. 2005;128:863–876.
 75. Bizymi N, Velegriaki M, Damianaki A, et al. Low proportion of myeloid derived suppressor cell populations in the peripheral blood of patients with chronic idiopathic neutropenia. *HemaSphere*. 2018;2 (suppl 1):103–104.
 76. Xin J, Breslin P, Wei W, et al. Necroptosis in spontaneously-mutated hematopoietic cells induces autoimmune bone marrow failure in mice. *Haematologica*. 2017;102:295–307.
 77. Ferrara JLM, Levine JE, Reddy P, et al. Graft-versus-host disease. *Lancet*. 2009;373:1550–1561.
 78. Koehn BH, Blazar BR. Role of myeloid-derived suppressor cells in allogeneic hematopoietic cell transplantation. *J Leukoc Biol*. 2017;102:335–341.
 79. Blazar BR, MacDonald KPA, Hill GR. Immune regulatory cell infusion for graft-versus-host disease prevention and therapy. *Blood*. 2018;131:2651–2660.
 80. Luyckx A, Schoupe E, Rutgeerts O, et al. G-CSF stem cell mobilization in human donors induces polymorphonuclear and mononuclear myeloid-derived suppressor cells. *Clin Immunol*. 2012;143:83–87.
 81. Vendramin A, Gimondi S, Bermema A, et al. Graft monocytic myeloid-derived suppressor cell content predicts the risk of acute graft-versus-host disease after allogeneic transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood stem cells. *Biol Blood Marrow Transplant*. 2014;20:2049–2055.
 82. Lv M, Zhao X-S, Hu Y, et al. Monocytic and promyelocytic myeloid-derived suppressor cells may contribute to G-CSF-induced immune tolerance in haplo-identical allogeneic hematopoietic stem cell transplantation. *Am J Hematol*. 2015;90:E9–E16.
 83. Yin J, Wang C, Huang M, et al. Circulating CD14(+) HLA-DR(-/low) myeloid-derived suppressor cells in leukemia patients with allogeneic hematopoietic stem cell transplantation: novel clinical potential strategies for the prevention and cellular therapy of graft-versus-host disease. *Cancer Med*. 2016;5:1654–1669.
 84. Highfill SL, Rodriguez PC, Zhou Q, et al. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. *Blood*. 2016;116:5738–5748.
 85. Wang D, Yu Y, Haarberg K, et al. Dynamic change and impact of myeloid-derived suppressor cells in allogeneic bone marrow transplantation in mice. *Biol Blood Marrow Transplant*. 2013;19:692–702.
 86. Le Blanc K, Jitschin R, Mougiakakos D. Myeloid-derived suppressor cells in allogeneic hematopoietic stem cell transplantation: a double-edged sword? *Oncimmunology*. 2013;2:7–9.
 87. Kusmartsev S, Cheng F, Yu B, et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. *Cancer Res*. 2003;63:4441–4449.
 88. Nefedova Y, Fishman M, Sherman S, et al. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. *Cancer Res*. 2007;67:11021–11028.
 89. Lee J-M, Seo J-H, Kim Y-J, et al. The restoration of myeloid-derived suppressor cells as functional antigen-presenting cells by NKT cell help and all-trans-retinoic acid treatment. *Int J Cancer*. 2012;131:741–751.
 90. Iclozan C, Antonia S, Chiappori A, et al. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. *Cancer Immunol Immunother*. 2009;6:247–253.
 91. Tomihara K, Fuse H, Heshiki W, et al. Gemcitabine chemotherapy induces phenotypic alterations of tumor cells that facilitate antitumor T cell responses in a mouse model of oral cancer. *Oral Oncol*. 2014;50:457–467.
 92. Annels NE, Shaw VE, Gabitass RF, et al. The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. *Cancer Immunol Immunother*. 2014;63:175–183.
 93. Porembka MR, Mitchem JB, Belt BA, et al. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid derived suppressor cells which promote primary tumor growth. *Cancer Immunol Immunother*. 2012;61:1373–1385.
 94. Krejčík J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. *Blood*. 2016;128:384–395.
 95. Trikha P, Carson WE. Signaling pathways involved in MDSC regulation. *Biochim Biophys Acta*. 2014;1846:55–65.
 96. Youn J, Kumar V, Collazo M, et al. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. *Nat Immunol*. 2013;14:211–220.
 97. Stone RM, Manley PW, Larson RA, et al. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. *Blood Adv*. 2018;2:444–453.
 98. Rosborough BR, Mathews LR, Matta BM, et al. FLT3 ligand mediates STAT3-independent expansion, but STAT-3 dependent activation of myeloid-derived suppressor cells. *J Immunol*. 2014;192:3470–3473.
 99. Duffy A, Zhao F, Haile L, et al. Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies. *Cancer Immunol Immunother*. 2013;62:299–307.
 100. Bruger AM, Dorhoi A, Esendagli G, et al. How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions. *Cancer Immunol Immunother*. 2018; <https://doi.org/10.1007/s00262-018-2170-8>.